HK1217670A1 - 調配物、其製造方法和用途 - Google Patents

調配物、其製造方法和用途

Info

Publication number
HK1217670A1
HK1217670A1 HK16105646.9A HK16105646A HK1217670A1 HK 1217670 A1 HK1217670 A1 HK 1217670A1 HK 16105646 A HK16105646 A HK 16105646A HK 1217670 A1 HK1217670 A1 HK 1217670A1
Authority
HK
Hong Kong
Prior art keywords
albu
bche
formulations
preparation
Prior art date
Application number
HK16105646.9A
Other languages
English (en)
Inventor
Zhao Qinghai
Luo Xia
Bock Jason
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1217670A1 publication Critical patent/HK1217670A1/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Mechanical Engineering (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16105646.9A 2013-01-15 2016-05-17 調配物、其製造方法和用途 HK1217670A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752740P 2013-01-15 2013-01-15
PCT/US2014/011401 WO2014113359A1 (en) 2013-01-15 2014-01-14 Formulations of albu-bche, preparation and uses thereof

Publications (1)

Publication Number Publication Date
HK1217670A1 true HK1217670A1 (zh) 2017-01-20

Family

ID=51165300

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105646.9A HK1217670A1 (zh) 2013-01-15 2016-05-17 調配物、其製造方法和用途

Country Status (7)

Country Link
US (1) US9409662B2 (zh)
EP (1) EP2945703A4 (zh)
AR (1) AR094481A1 (zh)
CA (1) CA2896793A1 (zh)
HK (1) HK1217670A1 (zh)
MX (1) MX2015009141A (zh)
WO (1) WO2014113359A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896793A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
MX2017016686A (es) * 2015-07-13 2018-03-26 Philip Morris Products Sa Produccion de una composicion formadora de aerosol.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048263T3 (es) 1988-11-01 1994-03-16 Sanol Arznei Schwarz Gmbh Composicion liofilizada de mdm y metodo para su fabricacion.
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20040087014A1 (en) 2000-11-28 2004-05-06 Huse William D Eukaryotic expression libraries and methods of use
US20030096401A1 (en) 2000-11-28 2003-05-22 Huse William D. Eukaryotic expression libraries and methods of use
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
US20030153062A1 (en) 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
IL142875A (en) 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
US7049121B2 (en) 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1458860A2 (en) 2001-12-21 2004-09-22 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
US20050136044A1 (en) 2003-12-04 2005-06-23 Watkins Jeffry D. Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
US20060039870A1 (en) 2004-08-20 2006-02-23 Turner Jeffrey D Pulmonary delivery of enzymatic medical countermeasures
NZ553057A (en) 2004-08-30 2009-12-24 Tercica Inc Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
WO2006119280A2 (en) 2005-05-03 2006-11-09 Handylab, Inc. Lyophilized pellets
US7438904B1 (en) 2005-10-04 2008-10-21 University Of Kentucky Research Foundation High-activity mutants of butyrylcholinesterase for ***e hydrolysis and method of generating the same
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
MY162844A (en) * 2006-07-10 2017-07-31 The Trustee Of Columbia Univ In The City Of New York Anti-***e compositions and treatment
EA023344B1 (ru) * 2009-01-16 2016-05-31 Тева Фармасьютикал Индастриз Лтд. Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AR079321A1 (es) * 2009-12-08 2012-01-18 Teva Pharma Fusiones de albumina y polipeptido butirilcolinesterasa (bche) para el tratamiento del abuso de ***a
SG194458A1 (en) 2011-04-12 2013-12-30 Endocyte Inc Solid pharmaceutical composition
WO2014093354A1 (en) 2012-12-12 2014-06-19 Teva Pharmaceutical Industries Ltd. Fusion of human growth hormone and albumin, formulation and uses thereof
CA2896793A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
MX2015008944A (es) 2013-01-15 2016-06-21 Teva Pharma Proceso de liofilizacion.

Also Published As

Publication number Publication date
US9409662B2 (en) 2016-08-09
MX2015009141A (es) 2016-03-16
US20140199283A1 (en) 2014-07-17
CA2896793A1 (en) 2014-07-24
WO2014113359A1 (en) 2014-07-24
EP2945703A4 (en) 2016-08-31
EP2945703A1 (en) 2015-11-25
AR094481A1 (es) 2015-08-05

Similar Documents

Publication Publication Date Title
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical preparations containing them
IL278214A (en) Preparations of azaindole compounds, methods for their preparation and their uses
ZA201602510B (en) Strigolactone formulations and uses thereof
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
EP2968304A4 (en) 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF
EP2968303A4 (en) OCTAHYDROCYCLOPENTAPYROLE AND THEIR PREPARATION AND USE
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HK1220920A1 (zh) 治療性組合物和其用途
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
HK1222563A1 (zh) 藥物組合物、製備及其用途
IL269622A (en) Preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)- secoisolariciresinol diglucoside
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
EP2988764A4 (en) COMPOSITIONS AGAINST DANDRUFF AND METHOD FOR USE THEREOF
SG11201510594YA (en) Mixtures of compounds, their preparation, and uses
IL246167A0 (en) Formulations of berberine and their uses
HK1217670A1 (zh) 調配物、其製造方法和用途
IL284405A (en) Pharmaceutical composition, preparation and uses thereof
AU2013904774A0 (en) Methods and Preparation and Use of Xanthorrhoeaceae Compositions
AU2013901834A0 (en) Formulations and Therapeutic Uses Thereof